Cargando…

A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data

BACKGROUND: Due to the high prevalence of mental disorders among people with opioid use disorder, the objective of this study was to determine the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment in Ont...

Descripción completa

Detalles Bibliográficos
Autores principales: Morin, Kristen A., Eibl, Joseph K., Gauthier, Graham, Rush, Brian, Mushquash, Christopher, Lightfoot, Nancy E., Marsh, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376938/
https://www.ncbi.nlm.nih.gov/pubmed/32703310
http://dx.doi.org/10.1186/s12954-020-00396-x
_version_ 1783562128588800000
author Morin, Kristen A.
Eibl, Joseph K.
Gauthier, Graham
Rush, Brian
Mushquash, Christopher
Lightfoot, Nancy E.
Marsh, David C.
author_facet Morin, Kristen A.
Eibl, Joseph K.
Gauthier, Graham
Rush, Brian
Mushquash, Christopher
Lightfoot, Nancy E.
Marsh, David C.
author_sort Morin, Kristen A.
collection PubMed
description BACKGROUND: Due to the high prevalence of mental disorders among people with opioid use disorder, the objective of this study was to determine the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment in Ontario, Canada. METHODS: We conducted a retrospective cohort study of patients enrolled in opioid agonist treatment between January 1, 2011, and December 31, 2015. Patients were stratified into two groups: those diagnosed with concurrent mental disorders and opioid use disorder and those with opioid use disorder only, using data from the Ontario Health Insurance Plan Database, Ontario Drug Benefit Plan Database. The primary outcome studied was all-cause mortality using data from the Registered Persons Database. Emergency department visits from the National Ambulatory Care Database, hospitalizations Discharge Abstract Database, and continuous retention in treatment, defined as 1 year of uninterrupted opioid agonist treatment using data from the Ontario Drug Benefit Plan Database were measured as secondary outcomes. Encrypted patient identifiers were used to link information across databases. RESULTS: We identified 55,924 individuals enrolled in opioid agonist treatment, and 87% had a concurrent mental disorder diagnosis during this period. We observed that having a mental disorder was associated with an increased likelihood of all-cause mortality (odds ratio (OR) 1.4; 95% confidence interval (CI) 1.2–1.5). For patients diagnosed with mental disorders, the estimated rate of ED visits per year was 2.25 times higher and estimated rate of hospitalization per year was 1.67 times higher than for patients with no mental disorders. However, there was no association between having a diagnosis of a mental disorder and 1-year treatment retention in OAT-adjusted hazard ratio (HR) = 1.0; 95% CI 0.9 to 1.1. CONCLUSION: Our findings highlight the consequences of the high prevalence of mental disorders for individuals with opioid use disorder in Ontario, Canada.
format Online
Article
Text
id pubmed-7376938
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73769382020-08-04 A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data Morin, Kristen A. Eibl, Joseph K. Gauthier, Graham Rush, Brian Mushquash, Christopher Lightfoot, Nancy E. Marsh, David C. Harm Reduct J Research BACKGROUND: Due to the high prevalence of mental disorders among people with opioid use disorder, the objective of this study was to determine the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment in Ontario, Canada. METHODS: We conducted a retrospective cohort study of patients enrolled in opioid agonist treatment between January 1, 2011, and December 31, 2015. Patients were stratified into two groups: those diagnosed with concurrent mental disorders and opioid use disorder and those with opioid use disorder only, using data from the Ontario Health Insurance Plan Database, Ontario Drug Benefit Plan Database. The primary outcome studied was all-cause mortality using data from the Registered Persons Database. Emergency department visits from the National Ambulatory Care Database, hospitalizations Discharge Abstract Database, and continuous retention in treatment, defined as 1 year of uninterrupted opioid agonist treatment using data from the Ontario Drug Benefit Plan Database were measured as secondary outcomes. Encrypted patient identifiers were used to link information across databases. RESULTS: We identified 55,924 individuals enrolled in opioid agonist treatment, and 87% had a concurrent mental disorder diagnosis during this period. We observed that having a mental disorder was associated with an increased likelihood of all-cause mortality (odds ratio (OR) 1.4; 95% confidence interval (CI) 1.2–1.5). For patients diagnosed with mental disorders, the estimated rate of ED visits per year was 2.25 times higher and estimated rate of hospitalization per year was 1.67 times higher than for patients with no mental disorders. However, there was no association between having a diagnosis of a mental disorder and 1-year treatment retention in OAT-adjusted hazard ratio (HR) = 1.0; 95% CI 0.9 to 1.1. CONCLUSION: Our findings highlight the consequences of the high prevalence of mental disorders for individuals with opioid use disorder in Ontario, Canada. BioMed Central 2020-07-23 /pmc/articles/PMC7376938/ /pubmed/32703310 http://dx.doi.org/10.1186/s12954-020-00396-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Morin, Kristen A.
Eibl, Joseph K.
Gauthier, Graham
Rush, Brian
Mushquash, Christopher
Lightfoot, Nancy E.
Marsh, David C.
A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
title A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
title_full A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
title_fullStr A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
title_full_unstemmed A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
title_short A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
title_sort cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (oat) across ontario, canada, using administrative health data
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376938/
https://www.ncbi.nlm.nih.gov/pubmed/32703310
http://dx.doi.org/10.1186/s12954-020-00396-x
work_keys_str_mv AT morinkristena acohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT eibljosephk acohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT gauthiergraham acohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT rushbrian acohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT mushquashchristopher acohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT lightfootnancye acohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT marshdavidc acohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT morinkristena cohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT eibljosephk cohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT gauthiergraham cohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT rushbrian cohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT mushquashchristopher cohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT lightfootnancye cohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata
AT marshdavidc cohortstudyevaluatingtheassociationbetweenconcurrentmentaldisordersmortalitymorbidityandcontinuoustreatmentretentionforpatientsinopioidagonisttreatmentoatacrossontariocanadausingadministrativehealthdata